179 related articles for article (PubMed ID: 16735714)
1. Neoadjuvant therapy with bevacizumab.
Gruenberger T; Gruenberger B; Scheithauer W
J Clin Oncol; 2006 Jun; 24(16):2592-3; author reply 2593-4. PubMed ID: 16735714
[No Abstract] [Full Text] [Related]
2. Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.
Abdalla EK; Eng C; Madary A; Vauthey JN;
Clin Colorectal Cancer; 2006 Mar; 5(6):436-9. PubMed ID: 16635283
[No Abstract] [Full Text] [Related]
3. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Gruenberger B; Tamandl D; Schueller J; Scheithauer W; Zielinski C; Herbst F; Gruenberger T
J Clin Oncol; 2008 Apr; 26(11):1830-5. PubMed ID: 18398148
[TBL] [Abstract][Full Text] [Related]
4. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
Booth C
J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
[No Abstract] [Full Text] [Related]
6. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
[TBL] [Abstract][Full Text] [Related]
7. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
[TBL] [Abstract][Full Text] [Related]
8. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
[TBL] [Abstract][Full Text] [Related]
9. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
[No Abstract] [Full Text] [Related]
10. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Pohlmann PR; Mernaugh RL; Goff LW
N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
[No Abstract] [Full Text] [Related]
11. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Copur MS; Norvell M; Obermiller A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445033
[No Abstract] [Full Text] [Related]
12. [A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].
Suzuki S; Shigaki N; Yokoyama S; Yamashita H; Sugita H; Arima N
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1545-7. PubMed ID: 21918360
[TBL] [Abstract][Full Text] [Related]
13. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
14. Combined-modality therapy for rectal cancer: future prospects.
Czito BG; Willett CG; Bendell JC
Clin Colorectal Cancer; 2007 Sep; 6(9):625-33. PubMed ID: 17945034
[TBL] [Abstract][Full Text] [Related]
15. Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Gibson TB; Grothey E; Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):233-9. PubMed ID: 18650191
[No Abstract] [Full Text] [Related]
16. 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy.
Funaioli C; Pinto C; Di Fabio F; Santini D; Ceccarelli C; De Raffaele E; Fanti S; Castellucci P; Longobardi C; Buggi F; Martoni AA
Tumori; 2007; 93(6):611-5. PubMed ID: 18338499
[TBL] [Abstract][Full Text] [Related]
17. Metastatic colorectal cancer: is surgery necessary?
Schmidt C
J Natl Cancer Inst; 2009 Aug; 101(16):1113-5. PubMed ID: 19671774
[No Abstract] [Full Text] [Related]
18. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Loupakis F; Di Maio M; Falcone A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
[No Abstract] [Full Text] [Related]
19. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection.
Dewdney A; Cunningham D; Barbachano Y; Chau I
Br J Cancer; 2012 May; 106(11):1718-21. PubMed ID: 22531628
[TBL] [Abstract][Full Text] [Related]
20. The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Clin Colorectal Cancer; 2003 Feb; 2(4):205-9. PubMed ID: 12620138
[No Abstract] [Full Text] [Related]
[Next] [New Search]
